FDA approves Amgen's T-cell engager for lung cancer, BioMarin announces layoffs, FDA delays Ascendis drug review [The good, the bad, the ugly]

Off Script: A Pharma Manufacturing Podcast

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — FDA approves Amgen T-cell engager for small cell lung cancer
The bad — BioMarin announces 170 layoffs
The ugly — FDA delays review of Ascendis hypoparathyroidism drug